



S2 Fig. Survival and ctDNA detection in patients with T-cell lymphoma (A). In newly diagnosed patients (n=73), patients with peripheral T-cell lymphomas and TFH lymphomas showed significantly worse overall survival than patients with systemic ALCL and CTCLs. (B) There was no significant difference of overall survival in patients with relapsed or refractory disease. (C, D) The detection of ctDNA mutation was higher in relapsed or refractory lymphomas (76%, 16/21) than in newly diagnosed lymphomas (51%, 37/73, p=0.047). (E, F) Patients with detected ctDNA mutations at diagnosis did not show significantly poorer overall survival than patients without detected ctDNA mutations in newly diagnosed TFH lymphomas and peripheral T-cell lymphomas. ALCL, anaplastic large cell lymphoma; CTCL, cutaneous T-cell lymphoma; ctDNA, circulating tumor DNA; PTCL, peripheral T-cell lymphoma; TFH, T follicular helper cell.